Robert A. Burger, MD

Associate Professor of
Clinical Obstetrics and Gynecology
Division of Gynecologic Oncology
E-mail: raburger@uci.edu
Make an Appointment

Clinical Interests

Dr. Burger, a board-certified obstetrician-gynecologist, is one of the most "up and coming" gynecologic oncologists in the United States. He has a strong and growing reputation in academic gynecologic oncology, as well as a strong track record of achievement in both the clinical and basic sciences. Dr. Burger's expertise and clinical interests are in the areas of women's health, gynecologic cancers, prevention and screening. Dr. Burger is an expert in performing radical pelvic surgery, including gastrointestinal and urologic procedures.

Research Interests

Dr. Burger's research interests are principally in the field of carcinogenesis, biomarkers and prevention, particularly as they relate to epithelial ovarian cancer and cervical cancer. This work is being conducted in the Division of Gynecologic Oncology, some through collaboration with other principal investigators at UCI and in national cooperative groups.

Dr. Burger's expertise in the medical informatics, database design and management, and statistical methods has benefited major projects within the Division of Gynecologic Oncology. For example, he established and coordinated a clinical and research database system, which is now networked across four medical campuses. In 1996, he was selected as the only candidate member of the Society of Gynecologic Oncologists (SGO) to be appointed to the Informatics Committee of that organization.

Education
Degree	Major	University	Year
Fellowship	Gynecologic Oncology	University of California, Irvine	1996
Residency	Obstetrics and Gynecology	University of Pennsylvania	1992
M.D.	Medicine	New York University	1988
A.B.	Biochemistry	Harvard University	1984

Board Certification

American Board of Obstetrics and Gynecology:
Obstetrics and Gynecology

American Board of Obstetrics and Gynecology:
Gynecologic Oncology

Selected Publications

Selected Book Chapters, Peer Reviewed
Granger GA, Gatanaga T, Burger RA, Grosen EA, Berman ML, DiSaia PJ. TNF, LT and IL-1 natural inhibitors (Soluble receptors and receptor antagonists) in women with ovarian cancer. In: F. Sharp, P. Mason, T. Blackett and J. Berek, eds. Ovarian Cancer 3. Hampshire: Chapman & Hall Ltd, 1994.

Keys HK, Piver S, Goldberg J, Kohorn E, Burger RA, Manetta A, Montz FJ. Stage I endometrial cancer with positive washings. In: M. Markman and J.L. Belinson, eds. Expert Consultations in Gynecological Cancers. New York: Marcel Dekker, Inc., 1996.

Burger RA, Ball HG, Cagnoni PJ, Jones RB, Bearman SI, Shpall EJ, Alberts D, Randall ME, Reichman BS. Microscopic residual ovarian cancer at second-look laparotomy. In: M. Markman and J.L. Belinson, eds. Expert Consultations in Gynecological Cancers. New York: Marcel Dekker, Inc., 1996.

Huinink WTB, Burger RA, Manetta AM, Pretorius RG, Homesley HD, Kiliackey M, Currie J. Recurrent ovarian germ-cell tumor (endodermal sinus tumor) following a response to chemotherapy. In: M. Markman and J.L. Belinson, eds. Expert Consultations in Gynecological Cancers. New York: Marcel Dekker, Inc., 1996.

Monk BJ, Burger RA. Endometrial and cervical carcinoma, in S.A. Vasilev, ed. Perioperative and Supportive Care in Gynecologic Oncology: Evidence-Based Management. New York: Wiley-Liss Inc., 2000.

Burger RA and Creasman WT. Gestational Trophoblastic Disease, in P.J. DiSaia and W.T. Creasman, eds. Clinical Gynecology. Philadelphia: W.B. Saunders/Harcourt Inc., 2001.

Selected Journal Articles, Peer reviewed
Gillette-Cloven N, Kyshtoobayeva A, Burger RA, Fruehauf JP. In vitro chemotherapeutic drug resistance and biomarker profiles are unique for histologic cell types of epithelial ovarian cancer. Gynecol Oncol 92: (1) 160-166, Jan. 2004. (Corresponding Author)

Fleming GF, Brunetto VL, Cella D, Look KY, Reid G, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22: (11) 2159-66, Jun. 2004.

Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn D. Association between serum levels of soluble TNF receptors/CA125 and progression in patients with epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) study. Cancer 101: (1) 106-15, Jul. 2004. (Corresponding Author)

Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol 94: (1) 61-6, Jul. 2004.

Thigpen JT, Brady MF, Homesley HD, Maltefano J, Dubeshter B, Burger RA, Liao S. Phase III Trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22: (19) 3902-8, Oct. 2004.

Tewari D, Monk BJ, Hunter M, Falkner CA, Burger RA. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma Invest New Drugs 22: (4) 465-80, Nov. 2004. (Corresponding Author)

Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96: (3) 902-5, Mar. 2005.